10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
JOHNSON & JOHNSON | |||
Ticker: JNJ Fiscal Year: 2021 | |||
Consolidated Statements of Earnings | |||
Period Ending Jan 2, 2022 10-K (Filed: Feb 17, 2022) | |||
(In Millions, except shares in Thousands) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Jan 2, 2022 | Jan 3, 2021 | Dec 29, 2019 | |
Sales to customers | $ 93,775 | 82,584 | 82,059 |
Cost of products sold | 29,855 | 28,427 | 27,556 |
Gross profit | 63,920 | 54,157 | 54,503 |
Selling, marketing and administrative expenses | 24,659 | 22,084 | 22,178 |
Research and development expense | 14,714 | 12,159 | 11,355 |
In-process research and development (Note 5) | 900 | 181 | 890 |
Interest income | (53) | (111) | (357) |
Interest expense, net of portion capitalized (Note 4) | 183 | 201 | 318 |
Other (income) expense, net | 489 | 2,899 | 2,525 |
Restructuring (Note 20) | 252 | 247 | 266 |
Earnings before provision for taxes on income | 22,776 | 16,497 | 17,328 |
Provision for taxes on income (Note 8) | 1,898 | 1,783 | 2,209 |
Net earnings | 20,878 | 14,714 | 15,119 |
Net earnings per share (Notes 1 and 15) | |||
Basic (in dollars per share) | 7.93 | 5.59 | 5.72 |
Diluted (in dollars per share) | 7.81 | 5.51 | 5.63 |
Average shares outstanding (Notes 1 and 15) | |||
Basic (in shares) | 2,632,100 | 2,632,800 | 2,645,100 |
Diluted (in shares) | 2,674,000 | 2,670,700 | 2,684,300 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
JOHNSON & JOHNSON | |||
Ticker: JNJ Fiscal Year: 2021 | |||
Consolidated Statements of Comprehensive Income | |||
Period Ending Jan 2, 2022 10-K (Filed: Feb 17, 2022) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Jan 2, 2022 | Jan 3, 2021 | Dec 29, 2019 | |
Net earnings | $ 20,878 | 14,714 | 15,119 |
Other comprehensive income (loss), net of tax | |||
Foreign currency translation | (1,079) | (233) | 164 |
Securities: | |||
Unrealized holding gain (loss) arising during period | (4) | 1 | 0 |
Reclassifications to earnings | 0 | 0 | 0 |
Net change | (4) | 1 | 0 |
Employee benefit plans: | |||
Prior service credit (cost), net of amortization | (169) | 1,298 | (18) |
Gain (loss), net of amortization | 4,318 | (1,135) | (714) |
Effect of exchange rates | 106 | (229) | (1) |
Net change | 4,255 | (66) | (733) |
Derivatives & hedges: | |||
Unrealized gain (loss) arising during period | (199) | 1,000 | (107) |
Reclassifications to earnings | (789) | (53) | 7 |
Net change | (988) | 947 | (100) |
Other comprehensive income (loss) | 2,184 | 649 | (669) |
Comprehensive income | 23,062 | 15,363 | 14,450 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
JOHNSON & JOHNSON | |||
Ticker: JNJ Fiscal Year: 2021 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Jan 2, 2022 10-K (Filed: Feb 17, 2022) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Jan 2, 2022 | Jan 3, 2021 | Dec 29, 2019 | |
Cash flows from operating activities | |||
Net earnings | $ 20,878 | 14,714 | 15,119 |
Adjustments to reconcile net earnings to cash flows from operating activities: | |||
Depreciation and amortization of property and intangibles | 7,390 | 7,231 | 7,009 |
Stock based compensation | 1,135 | 1,005 | 977 |
Asset write-downs | 989 | 233 | 1,096 |
Contingent consideration reversal | 0 | (1,148) | 0 |
Net gain on sale of assets/businesses | (617) | (111) | (2,154) |
Deferred tax provision | (2,079) | (1,141) | (2,476) |
Credit losses and accounts receivable allowances | (48) | 63 | (20) |
Changes in assets and liabilities, net of effects from acquisitions and divestitures: | |||
(Increase)/Decrease in accounts receivable | (2,402) | 774 | (289) |
Increase in inventories | (1,248) | (265) | (277) |
Increase in accounts payable and accrued liabilities | 2,437 | 5,141 | 4,060 |
Increase in other current and non-current assets | (1,964) | (3,704) | (1,054) |
(Decrease)/Increase in other current and non-current liabilities | (1,061) | 744 | 1,425 |
Net cash flows from operating activities | 23,410 | 23,536 | 23,416 |
Cash flows from investing activities | |||
Additions to property, plant and equipment | (3,652) | (3,347) | (3,498) |
Proceeds from the disposal of assets/businesses, net | 711 | 305 | 3,265 |
Acquisitions, net of cash acquired (Note 18) | (60) | (7,323) | (5,810) |
Purchases of investments | (30,394) | (21,089) | (3,920) |
Sales of investments | 25,006 | 12,137 | 3,387 |
Credit support agreements activity, net | 214 | (987) | 338 |
Other (primarily licenses and milestones) | (508) | (521) | 44 |
Net cash used by investing activities | (8,683) | (20,825) | (6,194) |
Cash flows from financing activities | |||
Dividends to shareholders | (11,032) | (10,481) | (9,917) |
Repurchase of common stock | (3,456) | (3,221) | (6,746) |
Proceeds from short-term debt | 1,997 | 3,391 | 39 |
Repayment of short-term debt | (1,190) | (2,663) | (100) |
Proceeds from long-term debt, net of issuance costs | 5 | 7,431 | 3 |
Repayment of long-term debt | (1,802) | (1,064) | (2,823) |
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 1,036 | 1,114 | 954 |
Credit support agreements activity, net | 281 | (333) | 100 |
Other | 114 | (294) | 475 |
Net cash used by financing activities | (14,047) | (6,120) | (18,015) |
Effect of exchange rate changes on cash and cash equivalents | (178) | 89 | (9) |
Increase/(Decrease) in cash and cash equivalents | 502 | (3,320) | (802) |
Cash and cash equivalents, beginning of year (Note 1) | 13,985 | 17,305 | |
Cash and cash equivalents, end of year (Note 1) | 14,487 | 13,985 | 17,305 |
Supplemental cash flow data | |||
Cash paid during the year for: | |||
Interest | 990 | 904 | 995 |
Interest, net of amount capitalized | 941 | 841 | 925 |
Income taxes | 4,768 | 4,619 | 4,191 |
Supplemental schedule of non-cash investing and financing activities | |||
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards | 1,811 | 1,937 | 1,736 |
Conversion of debt | 0 | 27 | 1 |
Acquisitions | |||
Fair value of assets acquired | 61 | 7,755 | 7,228 |
Fair value of liabilities assumed and noncontrolling interests | (1) | (432) | (1,418) |
Net cash paid for acquisitions (Note 18) | 60 | 7,323 | 5,810 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
JOHNSON & JOHNSON | ||
Ticker: JNJ Fiscal Year: 2021 | ||
Consolidated Balance Sheets | ||
Period Ending Jan 2, 2022 10-K (Filed: Feb 17, 2022) | ||
(In Millions, except shares in actual) | ||
As of | As of | |
Jan 2, 2022 | Jan 3, 2021 | |
Assets | ||
Current assets: | ||
Cash and cash equivalents (Notes 1 and 2) | $ 14,487 | 13,985 |
Marketable securities (Notes 1 and 2) | 17,121 | 11,200 |
Accounts receivable trade, less allowances for doubtful accounts $230 (2020, $293) | 15,283 | 13,576 |
Inventories (Notes 1 and 3) | 10,387 | 9,344 |
Prepaid expenses and other receivables | 3,701 | 3,132 |
Total current assets | 60,979 | 51,237 |
Property, plant and equipment, net (Notes 1 and 4) | 18,962 | 18,766 |
Intangible assets, net (Notes 1 and 5) | 46,392 | 53,402 |
Goodwill (Notes 1 and 5) | 35,246 | 36,393 |
Deferred taxes on income (Note 8) | 10,223 | 8,534 |
Other assets | 10,216 | 6,562 |
Total assets | 182,018 | 174,894 |
Liabilities and Shareholders Equity | ||
Current liabilities | ||
Loans and notes payable (Note 7) | 3,766 | 2,631 |
Accounts payable | 11,055 | 9,505 |
Accrued liabilities | 13,612 | 13,968 |
Accrued rebates, returns and promotions | 12,095 | 11,513 |
Accrued compensation and employee related obligations | 3,586 | 3,484 |
Accrued taxes on income (Note 8) | 1,112 | 1,392 |
Total current liabilities | 45,226 | 42,493 |
Long-term debt (Note 7) | 29,985 | 32,635 |
Deferred taxes on income (Note 8) | 7,487 | 7,214 |
Employee related obligations (Notes 9 and 10) | 8,898 | 10,771 |
Long-term taxes payable (Note 1) | 5,713 | 6,559 |
Other liabilities | 10,686 | 11,944 |
Total liabilities | 107,995 | 111,616 |
Commitments and Contingencies (Note 19) | ||
Shareholders equity | ||
Preferred stock without par value (authorized and unissued 2,000,000 shares) | 0 | 0 |
Common stock par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | 3,120 | 3,120 |
Accumulated other comprehensive income (loss) (Note 13) | (13,058) | (15,242) |
Retained earnings | 123,060 | 113,890 |
Stockholders' Equity before Treasury Stock | 113,122 | 101,768 |
Less: common stock held in treasury, at cost (Note 12) (490,878,000 shares and 487,331,000 shares) | 39,099 | 38,490 |
Total shareholders equity | 74,023 | 63,278 |
Total liabilities and shareholders equity | 182,018 | 174,894 |
External Links | |
JOHNSON & JOHNSON (JNJ) Fiscal Year 2021 | |
Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |